remodel trial semaglutide REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of Semaglutide-Mediated Remodeling of Adipose Tissue

In clinical studies, it helped people lose about 14% of their weightcomparable to the injection

Patients with documented pancreatic insufficiency or ongoing pain may face higher contraindication risk

#ObesityManagement #Semaglutide #Tirzepatide #Wegovy #GLP1 #Pharma #HealthcareInnovation #DiabetesCare To view or add a comment, sign in CagriSema vs Tirzepatide (REDEFINE 4): strong weight loss, but an important endpoint miss Novo Nordisk has announced headline results from the open-label phase 3 REDEFINE 4 trial comparing CagriSema (cagrilintide + semaglutide) vs tirzepatide 15 mg in obesity

By restoring growth hormone levels to their optimal range, it can mitigate issues related to stunted growth and hormonal imbalances

In a seminal study in diet-induced obese mice, 5-amino-1MQ administration led to a 35% reduction in mass and size, a 30% decrease in adipocyte size, and a 40% decrease in adipocyte volume in the rodents

It has potential therapeutic benefits, including gastrointestinal protection, wound and tissue healing, muscle recovery, anti-aging effects, and even possible cardiovascular and neurological benefits